Objective-To investigate the roles of inflammation and a cholesteryl ester transfer protein (CETP) polymorphism potentially related to recent findings demonstrating coronary risk with increasing high-density lipoprotein cholesterol (HDL-C) level. Methods and Results-A novel graphical exploratory data analysis tool allowed the examination of coronary risk in postinfarction patients relating to HDL-C and C-reactive protein levels. Results demonstrated a high-risk subgroup, defined by high HDL-C and C-reactive protein levels, exhibiting larger HDL particles and lower lipoprotein-associated phospholipaseA 2 levels than lower-risk patients. Subgroup CETP-associated risk was probed using a functional CETP polymorphism (TaqIB, rs708272). In the high-risk subgroup, multivariable modeling revealed greater risk for B2 allele carriers (less CETP activity) versus B1 homozygotes (hazard ratio, 2.41; 95% CI, 1.04 to 5.60; Pϭ0.04). Within the high-risk subgroup, B2 allele carriers had higher serum amyloid A levels than B1 homozygotes. Evidence also demonstrates that CETP genotypic differences in HDL subfraction distributions regarding non-HDL-C and lipoproteinassociated phospholipaseA 2 may potentially relate to impaired HDL remodeling. Conclusion-Postinfarction patients with high HDL-C and C-reactive protein levels demonstrate increased risk for recurrent events. Future studies should aim at characterizing altered HDL particles from such patients and at elucidating the mechanistic details related to inflammation and HDL particle remodeling. Such patients should be considered in drug trials involving an increase in HDL-C level. Key Words: atherosclerosis Ⅲ epidemiology Ⅲ lipoproteins Ⅲ risk factors Ⅲ cholesteryl ester transfer protein Ⅲ inflammation A n inverse association between high-density lipoprotein cholesterol (HDL-C) and cardiovascular disease (CVD) is well established. 1,2 However, recent studies 3-7 indicate that higher HDL-C levels may not always be protective. Consistent with this view is our identification in the Thrombogenic Factors and Recurrent Coronary Events (THROMBO) postinfarction study of a subgroup of nondiabetic patients with high C-reactive protein (CRP) levels who show recurrent risk with increasing HDL-C level. 3,7 Recently, we extended these studies to a healthy population (Prevention of Renal and Vascular End-Stage Disease study) to determine whether primary coronary risk acted similarly. 8 In addition to demonstrating a high-risk subgroup at high levels of HDL-C and CRP, the study also identified a second high-risk subgroup that was most apparent at high CRP levels but that occurred at low HDL-C levels, as might be expected from many previous studies. In view of the high CRP levels in the high HDL-C subgroups and the importance of inflammation in atherogenesis, 9,10 we speculated that HDL-C-associated risk derived from inflammation and oxidative stress-induced impairment of antiinflammatory and antiatherogenic features of HDL functionality. 3, 7 See accompanying article on page 1502 HDL particle remodeling is a prominent feature of HDL metabolism, whereby heterogeneous HDL particle subfractions continuously interconvert through interactions with other lipoproteins, transfer proteins, and lipolytic enzymes; as such, they play a major role in cholesterol transport. An important step in HDL remodeling is the transfer of cholesteryl ester from cholesterol-rich HDL particles in exchange for triglycerides from apolipoprotein B (apoB)-containing cholesterol-acceptor particles. This process is mediated by cholesteryl ester transfer protein (CETP). [11] [12] [13] Received on: 
A n inverse association between high-density lipoprotein cholesterol (HDL-C) and cardiovascular disease (CVD) is well established. 1, 2 However, recent studies [3] [4] [5] [6] [7] indicate that higher HDL-C levels may not always be protective. Consistent with this view is our identification in the Thrombogenic Factors and Recurrent Coronary Events (THROMBO) postinfarction study of a subgroup of nondiabetic patients with high C-reactive protein (CRP) levels who show recurrent risk with increasing HDL-C level. 3, 7 Recently, we extended these studies to a healthy population (Prevention of Renal and Vascular End-Stage Disease study) to determine whether primary coronary risk acted similarly. 8 In addition to demonstrating a high-risk subgroup at high levels of HDL-C and CRP, the study also identified a second high-risk subgroup that was most apparent at high CRP levels but that occurred at low HDL-C levels, as might be expected from many previous studies. In view of the high CRP levels in the high HDL-C subgroups and the importance of inflammation in atherogenesis, 9, 10 we speculated that HDL-C-associated risk derived from inflammation and oxidative stress-induced impairment of antiinflammatory and antiatherogenic features of HDL functionality. 3, 7 See accompanying article on page 1502 HDL particle remodeling is a prominent feature of HDL metabolism, whereby heterogeneous HDL particle subfractions continuously interconvert through interactions with other lipoproteins, transfer proteins, and lipolytic enzymes; as such, they play a major role in cholesterol transport. An important step in HDL remodeling is the transfer of cholesteryl ester from cholesterol-rich HDL particles in exchange for triglycerides from apolipoprotein B (apoB)-containing cholesterol-acceptor particles. This process is mediated by cholesteryl ester transfer protein (CETP). [11] [12] [13] In view of the important role of CETP in HDL particle remodeling, compromise in CETP action would be expected to impair remodeling. This could result in the accumulation of large cholesterol-rich HDL particles. Such particles, particularly in an inflammatory setting, might more readily undergo proatherogenic transformation. Thus, we hypothesized that compromised CETP activity would play a role in establishing the risk associated with high HDL-C and inflammation. To test this hypothesis, we probed the effects of decreased CETP activity on recurrent coronary event risk in THROMBO patients with high HDL-C and CRP levels using the TaqIB (rs708272) polymorphism of CETP, a marker with wellcharacterized differences in CETP activity 11, 12 and well suited to serve as a probe. 14,15
Methods

Study Population
The study population was composed of nondiabetic patients (Nϭ767) of the THROMBO postinfarction study. 16 Patients (with and without previous myocardial infarction [MI]) were enrolled after the index MI and followed up for recurrence (mean, 26 months). Recurrent coronary events included cardiac death, MI, or unstable angina (hospitalization during follow-up with an increase in either the frequency or the duration of angina symptoms or the development of new angina at rest, whichever occurred first, with both requiring ischemic ECG changes without enzyme elevation). THROMBO was performed with the approval of and according to the guidelines of the Research Subjects Review Board of participating institutions.
Blood Markers
Fasting blood specimens were drawn 2 months after the index MI. ApoB, total cholesterol, lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), apolipoprotein A-I (apoAI), HDL-C, triglyceride, glucose, insulin, lipoprotein(a) (Lp(a)), plasminogen activator inhibitor-1, CRP, von Willebrand factor antigen, fibrinogen, D-dimer, factor VII, and factor VIIa were quantified as previously described. 17 Serum amyloid A (SAA) was analyzed using high-sensitivity immunonephelometry. Gradient gel electrophoresis was used to separate HDL particles according to size, 18 with approximate size ranges as follows: H2b, 9.7 to 12.9 nm; H2a, 8.8 to 9.7 nm; H3a, 8.2 to 8.8 nm; H3b, 7.8 to 8.2 nm; and H3c, 7.2 to 7.8 nm. Subfraction cholesterol concentrations were estimated as fractional absorbance multiplied by HDL-C level.
Genotyping
Genotyping the CETP TaqIB polymorphism used a melting curve analysis method, as previously described, 19 based on G-nucleobase quenching to determine binding affinity to the polymerase chain reaction-amplified CETP sequence of 5Ј-carboxyfluorescein (FAM)-labeled probe (TCTGAACCCTAACTCGAAC) complementary to the TaqIB1 allele.
Statistical Analyses
Outcome event mapping, a graphical exploratory data analysis tool, was used to identify high-risk subgroups. 3, 7, 16, 20 Briefly, the approach begins with 3D scatter plots of outcome events (z-axis) over a bivariate risk domain (x-y plane) of 2 continuous biomarker variables. Patient outcome is coded as follows: 0, no outcome event; or 1, outcome event. Biomarker variables are rank transformed to more evenly distribute patients over the bivariate risk domain. Next, a smoothing algorithm is applied to the scatter plot, resulting in a surface (outcome event map) with height over the bivariate plane interpretable as estimated outcome rate. Peaks in mappings signal high-risk subgroups; specific delineation of high-risk subgroups is achieved by identifying all patients within the footprint of a region demarcated by a contour line of constant risk positioned at peak base.
Statistical and graphical analyses were performed using commercially available software (Statistica 8.0; StatSoft, Inc, Tulsa, Okla). Significant differences (PϽ0.05) between and among populations were assessed using the Mann-Whitney U test and the KruskalWallis test (with Bonferroni correction for post hoc testing). The 2 test was used to assess differences between polymorphism variant distributions. Correlation was assessed by the Spearman correlation coefficient. Cox proportional hazards multivariable regression was used to follow outcomes over time as a function of the dichotomized TaqIB polymorphism and biomarkers dichotomized as highest quartile versus combined 3 lower quartiles. Multivariable models were constructed including those biomarkers, and adjustment for those clinical covariates found to be significant in Cox univariate analysis (PϽ0.10). Significance in final multivariable models was at the PϽ0.05 level.
Results
Study Population
Clinical and laboratory characterizations of the study population were previously reported. 17 In brief, patients were a mean age of 58 years; 77.1% were men and 78.5% were white; and patients were overweight, with high triglycerides and slightly low HDL-C levels. TaqIB genotyping was available for 680 (88.7%) of the 767 patients of the study population, which was in Hardy-Weinberg equilibrium with respect to the polymorphism (B1B1, 34.3%; B1B2, 51.3%; and B2B2, 14.4%). The mean HDL-C levels for genotype variants were as follows (data given as MeanϮSD): B1B1, 0.98Ϯ0.29 mmol/L; B1B2, 1.00Ϯ0.28 mmol/L; and B2B2, 1.05Ϯ0.25 mmol/L (homozygotes significantly different, Pϭ0.01). The HDL median diameter and subfraction proportions were not different for genotype variants.
Risk Mapping as a Function of HDL-C and CRP
To investigate the effects of high HDL-C level and inflammation on recurrent coronary event risk, an outcome event mapping was generated as a function of HDL-C and CRP levels ( Figure 1 ). The mapping shows a major high-risk peak at high levels of HDL-C and CRP and a secondary peak at lower levels of HDL-C and CRP. The contour line corresponding to the mean outcome event rate (0.16 events per patient) of the total population served as a basis for defining a high-risk subgroup 16 corresponding to the major peak (nϭ166) and a background subgroup composed of the remaining lower-risk patients (nϭ601). Cox univariate regression analysis was performed comparing high-risk patients with the background subgroup (hazard ratio, 1.81; 95% CI, 1.24 to 2.65; Pϭ0.002). Table 1 presents results comparing clinical and laboratory parameters between the groups. The high-risk subgroup versus the remaining patients demonstrated more female and black patients; higher levels of HDL-C, apoA1, total cholesterol, and inflammatory markers (CRP, von Willebrand factor, fibrinogen, D-dimer, and SAA); and lower levels of triglycerides and Lp-PLA 2 . To assess whether female enrichment of the high-risk subgroup resulted from the known association of higher levels of HDL-C and CRP in women, separate Cox univariate analyses were run for high-risk female versus background patients (hazard ratio, 1.87; 95% CI, 1.12 to 3.11; Pϭ0.02) and high-risk male versus background patients (hazard ratio, 1.32; 95% CI, 1.04 to 1.68; Pϭ0.02). Results indicated significant risk in each case. Table 2 presents comparison results for HDL median particle diameter and percentage of HDL-C in HDL subfractions. Overall, results demonstrated larger HDL particles in the high-risk subgroup.
Clinical and Biomarker Characterization of TaqIB Effects
Comparing high-risk with background subgroups, TaqIB distributions were not different (B1B1, 32.9% versus 34.6%; B1B2, 50.3% versus 51.6%; and B2B2, 16.8% versus 13.8%; Pϭ0.66). To assess the potential of a dosage effect of the polymorphism on recurrent coronary event rates, Table 3 provides the following as a function of genotype: recurrence rates (given in percentages), number of patients, and probability values for the comparison of recurrence rates in the high-risk subgroup versus the background subgroup. The table reveals increasing risk in the high-risk subgroup relative to the background subgroup with B2 allele dose.
Before more definitive assessment of the role of CETP action regarding HDL-C-associated risk, TaqIB polymorphism effects on clinical and biomarker levels in the high-risk subgroup were assessed for all parameters listed in Tables 1  and 2 
Risk Association of TaqIB Within the High-Risk Subgroup
To assess the role of CETP action regarding risk within the high-risk subgroup, the TaqIB polymorphism was used as a probe based on well-characterized allele-associated differences in CETP activity. 11, 12 Thus, multivariable Cox proportional hazards modeling was performed using the following as predictor variables: the dichotomized polymorphism (B2 allele carriers versus B1 homozygotes) and dichotomized biomarkers ( Figure 2B ). The mapping for B2 carriers shows a major peak similar to the high-risk peak of Figure 1 ; the mapping for B1 homozygotes does not show this peak. Forcing age, sex, race, and statin use (Table 1 ) into multivariable models gave essentially the same results regarding TaqIB and apoB. To assess interaction between the polymorphism and apoB, separate Cox models were run for patients with a low apoB level and those with a high apoB level. Results demonstrated nonsignificance for the TaqIB hazard ratio in patients with a low apoB level (Pϭ0.29); a trend emerged (Pϭ0.06) for patients with a high apoB level, indicating focused TaqIB-associated risk.
TaqIB Differential Functional Effects
To demonstrate TaqIB-associated functional effects, we monitored HDL particle subfractions as a function of cholesterol-acceptor levels (VLDL, intermediate-density lipoprotein, and LDL), approximated as non-HDL-C levels. The median non-HDL-C level was used to dichotomize subgroups. Data (means, SDs, and percentage differences) in HDL subfractions for patients with a high and a low non-HDL-C level in the high-risk and background subgroups are given in Table  4 as a function of TaqIB genotypes. For B1B1 patients in the high-risk subgroup, the table shows large subfraction differences for patients with a high versus a low non-HDL-C level, deriving from fewer large HDL particles (H2b) and more smaller particles (especially H3b) as a function of high non-HDL-C level. For B2 allele carriers in the high-risk subgroup, corresponding differences were smaller and nonsignificant. Differences in the entire background subgroup were generally small and resembled those of B2 allele carriers in the high-risk subgroup. Similar analyses were also performed using triglycerides instead of non-HDL-C to approximate cholesterolacceptor levels. Marked differences among TaqIB genotypes were not demonstrated. Regarding previous findings related to SAA (high levels in the high-risk subgroup for B2 carriers) and Lp-PLA 2 (low levels in the high-risk subgroup), further studies were undertaken to assess potential roles for these parameters in altered HDL remodeling. Spearman correlation coefficients of HDL-C subfraction concentrations, with SAA and Lp-PLA 2 in the high-risk subgroup as a function of TaqIB, were generated, giving the following results: for SAA, essentially no significant correlation (data not shown); for Lp-PLA 2 
Discussion
In a nondiabetic postinfarction population using a novel graphical exploratory data analysis tool, a subgroup of patients at high risk for recurrent coronary events was identified at high HDL-C and CRP levels. Subgroup patients had low levels of Lp-PLA 2 and large HDL particles. These results parallel findings from a primary coronary events study (the Prevention of Renal and Vascular End-Stage Disease study) that also identified a high-risk subgroup at high HDL-C and CRP levels with presumptive evidence of large HDL particles. 8 Thus, in both primary and secondary coronary event studies, high-risk subgroups with large HDL particles have been identified at high levels of HDL-C and CRP. Unlike the Prevention of Renal and Vascular End-Stage Disease study, 8 the current study did not show a prominent high-risk subgroup at a low HDL-C level. This may relate to different pathophysiologic mechanisms underlying primary and secondary coronary risk development.
Further studies in the high-risk subgroup were performed with TaqIB, a functional CETP polymorphism, to probe early stages of HDL metabolism. Genotype distributions in the study population were similar to values in healthy populations, indicating the absence of genotype-related survival effects for postinfarction patients. 11, 12 For blood markers, B2 allele carriers (less CETP activity) had higher levels of triglycerides and SAA. Multivariable modeling indicated only TaqIB (B2 allele carriers at higher risk) and high apoB levels as significant risk predictors. Support for TaqIB functional effects was suggested by genotypic differences in HDL subfraction distributions as a function of non-HDL-C (rough measure of cholesterol-acceptor particles). Further support resulted from correlation studies of Lp-PLA 2 with HDL subfractions showing, for B1 homozygotes, cholesterol shift with higher Lp-PLA 2 from large to small particle subfractions, especially to H3c. This was consistent with the reported preferential association of Lp-PLA 2 in HDL parti- HDL-C, high-density lipoprotein cholesterol. *Data are given as meanϮSD. To convert HDL-C from mmol/L to mg/dL, divide by 0.0259. †Differences in HDL-C subfraction cholesterol for patients with a high non-HDL-C level vs those with a low non-HDL-C level. ‡PϽ0.05.
cles with the H3c subfraction. 21 Such a shift was not seen in B2 allele carriers. The B2 allele (decreased CETP activity and increased HDL-C level) associated with risk in the high-risk subgroup. Recent meta-analyses 11, 12 of TaqIB suggest lower B2-associated CVD risk, whereas other studies suggest a higher risk. 12 Such differences have been attributed to study type, with population-based studies demonstrating high B2 alleleassociated risk and high-risk population studies demonstrating low B2 allele-associated risk. 12 To reduce CVD risk, recent efforts have attempted to increase HDL-C levels. There are striking similarities between current study findings and clinical trials with the drug, torcetrapib. [22] [23] [24] [25] [26] In both cases, CVD events were associated with increased HDL-C levels. Although the off-target effects of torcetrapib, especially increased blood pressure, could not be excluded as a factor, 22 this is irrelevant in the current study because reduced CETP activity did not occur pharmacologically. Indeed, a recent study 15 comparing torcetrapib with the B2 allele revealed concordant effects on blood lipids and lipoproteins but increased blood pressure only for torcetrapib. The current approach allows the identification of high-risk individuals embedded in larger patient populations. Excluding such patients may allow validation of the use of such drugs in selected populations.
We believe that B2 allele-associated risk derives in some part from proatherogenic transformation of HDL. 9, 27, 28 Although our finding of differential effects on HDL subfraction distributions in B2 allele carriers versus B1 homozygotes as a function of non-HDL-C demonstrated interaction of TaqIB genotypes with a measure of cholesterol-acceptor particle levels, definitive conclusions regarding a potential role for impaired HDL particle remodeling in the establishment of B2-associated risk were not possible from such results be- 9, 27, 28, 30 Consistent with this notion are our findings in the high-risk subgroup of lower levels of Lp-PLA 2 ; in B2 allele carriers, we found higher levels of SAA, an apolipoprotein closely associated with HDL. [31] [32] [33] [34] High SAA levels displace apoA1 in HDL, resulting in loss of apoA1 functionality and impaired activity of lecithin:cholesterol acyltransferase, paraoxonase, and Lp-PLA 2 27 (especially notable in view of our finding of lower Lp-PLA 2 in the high-risk subgroup). The fact that lower Lp-PLA 2 levels were associated with the high-risk subgroup, contrary to the generally held belief that high Lp-PLA 2 levels are proatherogenic, may be reflective of the notion that Lp-PLA 2 in LDL is proatherogenic; in contrast, Lp-PLA 2 in HDL is antiatherogenic. 21, 30 Other proatherogenic effects of SAA on HDL include increased cholesterol delivery to vascular walls because SAAenriched HDL binds strongly to vascular proteoglycans, facilitating cholesterol retention and further HDL alteration. 31, 33 Study limitations included lack of direct evidence of impaired HDL particle remodeling in association with the B2 allele. Also, no direct evidence was provided about the role of inflammation in dysfunctional HDL, although high SAA in B2 carriers was highly suggestive. Additional risk factor data (exercise, diet, ethanol, mental status, and social support) were lacking. Specifically, focused future studies could be oriented at addressing all these issues and replicating current study findings. The strengths of the study included use of an exploratory data analysis tool that can identify risk-based subgroups anywhere in a bivariate risk domain.
Study results demonstrate that high levels of HDL-C and CRP define a subgroup of postinfarction patients at high risk for recurrent coronary events. In addition, the B2 allele of the TaqIB polymorphism of CETP was associated with recurrent events in the high-risk subgroup. Future studies should aim to examine specific mechanisms leading to HDL dysfunction and to characterize resultant particles. Such patients should be considered in future drug trials involving an increase in HDL-C levels because this could aid in validating valuable approaches by excluding such patients.
